Dry Eye Disease study: Propylene Glycol
Official title Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease
ClinicalTrials.gov ID: NCT07676084
What this study is testing
What is Preservative Free Polyethylene glycol 400 0.25%?
An investigational lubricating eye drop being studied as a potential treatment for dry eye disease (DED). It is designed to coat the eye surface and retain moisture, helping to alleviate dryness.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how well OTC lubricating eye drops are tolerated and whether they improve symptoms and vision in dry eye patients.
- Who it's for
- Adults who have been diagnosed with dry eye disease.
- What's involved
- Participants will use the eye drops as directed and report any side effects, symptoms, and vision changes during the study.
- Time commitment
- The study lasts for a short period with a few clinic visits to assess tolerability and outcomes.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Be at least 18 years of age, male or female
- Able to provide written voluntary informed consent
- Able and willing to adhere to the protocol instructions, including participation in all study visits
- Subject-reported symptoms or history consistent with dry eye for at least 6 months prior to Screening/Baseline (Visit 1)
- Ocular Surface Disease Index (OSDI) score \>13
You likely can't join if
- Note: All ocular exclusion criteria apply to either eye.
- DED secondary to destruction of conjunctival goblet cells due to ocular trauma (eg, alkali burns) or ocular or systemic condition (eg...
- Any abnormal lid or corneal anatomy that would interfere with eyelid closure or create an irregular ocular tear film
- Any active ocular infection, inflammation, or ocular allergy
- Have undergone ocular surgery or laser refractive surgery within 9 months prior to Screening/Baseline (Visit 1)
- Use of LipiFlow® procedure, intense pulse light procedure, or any kind of other procedure affecting meibomian glands within 6 months prior to...
See the full eligibility criteria
- Be at least 18 years of age, male or female
- Able to provide written voluntary informed consent
- Able and willing to adhere to the protocol instructions, including participation in all study visits
- Subject-reported symptoms or history consistent with dry eye for at least 6 months prior to Screening/Baseline (Visit 1)
- Ocular Surface Disease Index (OSDI) score \>13
- Note: All ocular exclusion criteria apply to either eye.
- DED secondary to destruction of conjunctival goblet cells due to ocular trauma (eg, alkali burns) or ocular or systemic condition (eg, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, Vitamin A deficiency)
- Any abnormal lid or corneal anatomy that would interfere with eyelid closure or create an irregular ocular tear film
- Any active ocular infection, inflammation, or ocular allergy
- Have undergone ocular surgery or laser refractive surgery within 9 months prior to Screening/Baseline (Visit 1)
- Use of LipiFlow® procedure, intense pulse light procedure, or any kind of other procedure affecting meibomian glands within 6 months prior to Screening/Baseline (Visit 1)
- Occlusion of the ocular puncta within 30 days prior to Screening/Baseline (Visit 1)
- Have worn contact lenses within 3 days prior to Screening/Baseline (Visit 1) or planned wear during the study
- Use of topical prescription products for dry eye, including topical ocular anti inflammatories (eg, cyclosporine, lifitegrast), corticosteroids, MIEBO® (perfluorohexyloctane ophthalmic solution), or TRYPTYR® (alcotremon...
- Use of any eye drops (prescription or OTC, such as artificial tears or Lumify®) and/or TrueTear™ device (intranasal tear neurostimulator) within 24 hours prior to Screening/ Baseline (Visit 1)
- Changes in any systemic medications known to impact tear production (eg, antihistamines, antidepressants, hormone replacement therapy, etc.) within 3 months prior to Screening/Baseline (Visit 1)
- Have a serious or uncontrolled systemic disease (eg, diabetes, rheumatoid arthritis, lupus, hypertension, malignancy) that, in the opinion of the Investigator, will interfere with the study or interpretation of study...
The study team makes the final eligibility decision.
Where it is enrolling
- Andover, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Andover, Massachusetts, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.